Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX), a biopharmaceutical company, is committed to discovering, developing and commercializing superior cancer therapeutics. The company’s proprietary platform, AvalonRx®, is designed to discover and develop therapeutics for pathways that have been characterized as “undruggable” in the past. For further information, visit the Company’s web site at www.avalonrx.com.
- 17 years ago
QualityStocks
Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX)
Tags Rodman & Renshaw
Related Post
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
Safe Pro Group delivers AI, drone-based services, and ballistic protective gear, to customers in the…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…